Antibody-drug conjugates (ADCs) are transforming oncology by delivering cytotoxic payloads to cancercells via antibody targeting. Despite 15 FDA approvals, ADCs remain limited by toxicity and resistance,as current payloads lack cancer selectivity. Cancentus is developing a novel, cancer-selective payload with a unique mechanism to enhance selectivity, improve efficacy across cancers and overcome resistance, aiming to expand the therapeutic window of ADCs.